The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Combinatorial targeting of TSLP, IL-25, and IL-33 in type 2 cytokine–driven inflammation and fibrosis
Open accessAbstract
Thymic stromal lymphopoietin (TSLP), interleukin-25 (IL-25), and IL-33 are important initiators of type 2-associated mucosal inflammation and immunity. However, their role in the maintenance of progressive type 2 inflammation and fibrosis is much less clear. Using chronic models of helminth infection and allergic lung inflammation, we show that collective disruption of TSLP, IL-25, and IL-33 signaling suppresses chronic and progressive type 2 cytokine-driven inflammation and fibrosis. In a schistosome lung granuloma model or during chronic Schistosoma mansoni infection in the liver, individual ablation of TSLP, IL-25, or IL-33/ST2 had no impact on the development of IL-4/IL-13-dependent inflammation or fibrosis. However, significant reductions in granuloma-associated eosinophils, hepatic fibrosis, and IL-13-producing type 2 innate lymphoid cells (ILC2s) were observed when signaling of all three mediators was simultaneously disrupted. Combined blockade through monoclonal antibody (mAb) treatment also reduced IL-5 and IL-13 expression during primary and secondary granuloma formation in the lungs. In a model of chronic house dust mite-induced allergic lung inflammation, combined mAb treatment did not decrease established inflammation or fibrosis. TSLP/IL-33 double-knockout mice treated with anti-IL-25 mAb during priming, however, displayed decreased inflammation, mucus production, and lung remodeling in the chronic phase. Together, these studies reveal partially redundant roles for TSLP, IL-25, and IL-33 in the maintenance of type 2 pathology and suggest that in some settings, early combined targeting of these mediators is necessary to ameliorate progressive type 2-driven disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“integrin receptors that interact with the extracellular matrix were recently shown to preferentially activate TGF-β signaling and production of IL-17A while antagonizing the production of type 2 cytokines142”
From Fibrosis: from mechanisms to medicines (2020) · cites this paper as [142]
In the citing paper
“several studies have revealed substantial cross-regulation between IL-17A and IL-13110,143, with marked upregulation of the opposing pathway when only one mechanism was targeted therapeutically136,142,144,145”
From Fibrosis: from mechanisms to medicines (2020) · cites this paper as [142]
Citations
Cites
Functional diversity of helper T lymphocytes
Abbas, A. K., Murphy, K. M., & Sher, A. (1996) · Nature · doi:10.1038/383787a0 · Cited by 4,450 · cited 1×
“In addition to suppressing the proinflammatory activity of type 1 immune responses (2), type 2 immunity regulates wound healing (3), metabolic homeostasis (4), and immunity to several extracellular parasites (5).”
BackgroundSchmitz, J., Owyang, A., Oldham, E., Song, Y., Murphy, E., McClanahan, T. K., Zurawski, G., Moshrefi, M., Qin, J., Li, X., et al. (2005) · Immunity · doi:10.1016/j.immuni.2005.09.015 · Cited by 3,710
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
Wynn, T. A., & Ramalingam, T. R. (2012) · Nature Medicine · doi:10.1038/nm.2807 · Cited by 3,541
Self-citationPetry, F. E. (1997) · Kluwer Academic Publishers eBooks · Cited by 2,303
Human epithelial cells trigger dendritic cell–mediated allergic inflammation by producing TSLP
Soumelis, V., Reche, P. A., Kanzler, H., Yuan, W., Edward, G., Homey, B., Gilliet, M., Ho, S., Antonenko, S., Lauerma, A., et al. (2002) · Nature Immunology · doi:10.1038/ni805 · Cited by 2,183
Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity
Neill, D. R., Wong, S. H., Bellosi, A., Flynn, R. J., Daly, M., Langford, T. K. A., Bucks, C., Kane, C. M., Fallon, P. G., Pannell, R., et al. (2010) · Nature · doi:10.1038/nature08900 · Cited by 1,938
The immunological and genetic basis of inflammatory bowel disease
Bouma, G., & Strober, W. (2003) · Nature Reviews Immunology · doi:10.1038/nri1132 · Cited by 1,767
Fibrotic disease and the TH1/TH2 paradigm
Wynn, T. A. (2004) · Nature Reviews Immunology · doi:10.1038/nri1412 · Cited by 1,765 · cited 2×
“In addition to suppressing the proinflammatory activity of type 1 immune responses (2), type 2 immunity regulates wound healing (3), metabolic homeostasis (4), and immunity to several extracellular parasites (5).”
BackgroundSelf-citationMacrophage-mediated inflammation in metabolic disease
Chawla, A., Nguyen, K. D., & Goh, Y. P. S. (2011) · Nature reviews. Immunology · doi:10.1038/nri3071 · Cited by 1,314 · cited 1×
“In addition to suppressing the proinflammatory activity of type 1 immune responses (2), type 2 immunity regulates wound healing (3), metabolic homeostasis (4), and immunity to several extracellular parasites (5).”
BackgroundIL-25 Induces IL-4, IL-5, and IL-13 and Th2-Associated Pathologies In Vivo
Fort, M. M., Cheung, J., Yen, D., Li, J., Zurawski, S. M., Lo, S., Menon, S., Clifford, T., Hunte, B., Lesley, R., et al. (2001) · Immunity · doi:10.1016/s1074-7613(01)00243-6 · Cited by 1,203
Research works printed but not linked: 2
- 10.1002/1521-4141(200205)32:5<1428::AID-IMMU1428>3.0.CO;2-0 · doi:10.1002/1521-4141(200205)32:5<1428::aid-immu1428>3.0.co;2-0
- T. A. Wynn L. Barron R. W. Thompson S. K. Madala M. S. Wilson A. W. Cheever T. Ramalingam in Current Protocols in Immunology John E. Coligan et al. Eds. (John Wiley & Sons Inc. New York 2011).
Cited by
Items 101–188 of 188
IL-33 gene variants and protein expression in pediatric Tunisian asthmatic patients
Charrad, R., Kaabachi, W., Berraïes, A., Hamzaoui, K., & Hamzaoui, A. (2017) · Cytokine · doi:10.1016/j.cyto.2017.09.028 · Cited by 18
Brazee, P. L., Allen, N., Knipe, R. S., Redente, E. F., & Saux, C. J. L. (2025) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/a-2649-9402 · Cited by 27
Neutrophil extracellular traps (NETs) and fibrotic diseases
Wu, X., & Yang, Y. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112085 · Cited by 20
Type 2 Innate Lymphoid Cells in Liver and Gut: From Current Knowledge to Future Perspectives
Ochel, A., Tiegs, G., & Neumann, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081896 · Cited by 20
Sphingomyelin maintains the cutaneous barrier via regulation of the STAT3 pathway
Komuro, M., Nagane, M., Fukuyama, T., Luo, X., Hiraki, S., Miyanabe, M., Ishikawa, M., Niwa, C., Murakami, H., Okamoto, M., et al. (2022) · The FASEB Journal · doi:10.1096/fj.202100721rr · Cited by 19
Synthesis and biological evaluation of peptide-derived TSLP inhibitors
Park, S., Park, Y., Son, S., Lee, K., Jung, Y. W., Lee, K. Y., Jeon, Y. H., & Byun, Y. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.09.010 · Cited by 17
de Oliveira, V. G., Rodrigues, V. F., Moreira, J. M. P., Rodrigues, J. L., Maggi, L., Resende, S. D., & Negrão‐Corrêa, D. A. (2021) · Cytokine · doi:10.1016/j.cyto.2021.155701 · Cited by 17
Innate lymphoid cells and fibrotic regulation
Horsburgh, S., Todryk, S. M., Ramming, A., Distler, J. H. W., & O’Reilly, S. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.08.022 · Cited by 18
Abebayehu, D., Pfaff, B. N., Bingham, G. C., Miller, A. E., Kibet, M., Ghatti, S., Griffin, D. R., & Barker, T. H. (2024) · Science Advances · doi:10.1126/sciadv.adf2675 · Cited by 19
Advances and Evolving Concepts in Allergic Asthma
Tung, H.-Y., Li, E., Landers, C. T., Nguyen, A., Kheradmand, F., Knight, J., & Corry, D. B. (2018) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0037-1607981 · Cited by 16
Chia, S. B., Nolin, J. D., Aboushousha, R., Erickson, C. S., Irvin, C. G., Poynter, M. E., van der Velden, J. L. J., Taatjes, D. J., van der Vliet, A., Anathy, V., et al. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101720 · Cited by 16
Martin, K. E., Kalelkar, P. P., Coronel, M. M., Theriault, H. S., Schneider, R. S., & García, A. J. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121601 · Cited by 15
Wang, W. W., Pan, Y. L., Yu, H. W., Zhang, B., & Shao, S. W. (2019) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-019-05369-w · Cited by 13
Majewski, S., Szewczyk, K., Białas, A. J., Miłkowska-Dymanowska, J., Górski, P., & Piotrowski, W. J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101590 · Cited by 14
“Lack of uniform association between alarmins in the serum and EBC may be a consequence of different biologic expression of the epithelial alarmins in the systemic and local lung compartments and overlapping functional activities of these cytokines [43,44].”
BackgroundMaggi, L., Rocha, I. C., Camelo, G. M. A., Fernandes, V. R., & Negrão‐Corrêa, D. A. (2020) · Cytokine · doi:10.1016/j.cyto.2020.155390 · Cited by 14
Interleukin 25 and its biological features and function in intestinal diseases
Jiang, W., Wang, Z., Zhang, J., & Li, M. (2023) · Central European Journal of Immunology · doi:10.5114/ceji.2022.124416 · Cited by 14
Tuft cells are required for a rhinovirus-induced asthma phenotype in immature mice
Li, Y., Han, M., Singh, S., Breckenridge, H. A., Kreger, J. E., Stroupe, C. C., Sawicky, D. A., Kuo, S., Goldsmith, A. M., Ke, F., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.166136 · Cited by 13
“The innate cytokines IL-25, IL-33 and thymic stromal lymphopoietin (TSLP) have additive effects on ILC2 function and augmenting cellular 166136-INS-RG-1-RV-3 responsiveness to each other via upregulation of their cellular receptors (16, 17).”
BackgroundZheng, R., Chen, Y., Shi, J., Wang, K., Huang, X., Sun, Y., & Yang, Q. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00207 · Cited by 16
“targeting may be required to temper type 2-driven inflammation (Vannella et al., 2016).”
BackgroundInnate lymphoid cells are double‐edged swords under the mucosal barrier
Duan, Z., Liu, M., Yuan, L., Du, X., Wu, M., Yang, Y., Wang, L., Zhou, K., Yang, M., Zou, Y., et al. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16856 · Cited by 12
Association of Circulating Fibrocytes With Fibrostenotic Small Bowel Crohn’s Disease
Ueno, A., Jijon, H. B., Peng, R., Sparksman, S., Mainoli, B., Filyk, A., Li, Y., Wilson, S. R., Novak, K. L., Panaccione, R., et al. (2021) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izab157 · Cited by 14
Zhang, P., Liu, Z., Peng, L., Zhou, J., Wang, M., Li, J., Lu, H., Hu, C., Zhao, L., Yang, H., et al. (2021) · Rheumatology · doi:10.1093/rheumatology/keab610 · Cited by 13
Wang, C., Lin, W., Wang, Y., & Fu, L. (2020) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202000593 · Cited by 13
Role and mechanism of WNT5A in benzo(a)pyrene-induced acute lung injury and lung function decline
Fan, L., Wang, B., Ma, J., Ye, Z., Nie, X., Cheng, M., Xie, Y., Gu, P. H., Zhang, Y., You, X., et al. (2023) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2023.132391 · Cited by 12
The potential roles of interleukin-25 in infectious diseases
Wu, J., Zhang, F., Tao, H., Nawaz, W., Chen, D., & Wu, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.986118 · Cited by 15
“reported that IL-25 induced by helminth infection was associated with the progression of pulmonary fibrosis (58).”
BackgroundLuzina, I. G., Lockatell, V., Courneya, J.-P., Mei, Z., Fishelevich, R., Kopach, P., Pickering, E. M., Kang, P. H., Krupnick, A. S., Todd, N. W., et al. (2022) · Cellular Immunology · doi:10.1016/j.cellimm.2022.104657 · Cited by 12
Webb, L., Phythian-Adams, A., Costain, A., Brown, S., Lundie, R., Forde-Thomas, J., Cook, P., Jackson-Jones, L., Marley, A. K., Smits, H., et al. (2021) · ImmunoHorizons · doi:10.4049/immunohorizons.2100071 · Cited by 9
Re-thinking our understanding of immunity: Robustness in the tissue reconstruction system
Truchetet, M., & Pradeu, T. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.02.013 · Cited by 13
Critical and diverse role of alarmin cytokines in parasitic infections
Xing, Z., Liu, S., & He, X. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1418500 · Cited by 11
“…IL-33/ST2 had no impact on the progression of Schistosoma mansoni induced type 2 in fl ammation or fi brosis, whereas simultaneous disruption of all three mediators resulted in signi fi cant reductions in granuloma-associated eosinophils, fi brosis, and IL-13 – producing ILC2 (Vannella et al., 2016).”
Initiation, Persistence and Exacerbation of Food Allergy
Jiménez‐Saiz, R., Chu, D. K., Waserman, S., & Jordana, M. (2017) · Birkhäuser advances in infectious diseases · doi:10.1007/978-3-319-69968-4_7 · Cited by 11
The Immunology of Asthma and Allergic Rhinitis
Kiboneka, A., & Kibuule, D. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.86964 · Cited by 10
Xu, Y. Q. (2019) · The Anatolian Journal of Cardiology · doi:10.14744/anatoljcardiol.2019.24265 · Cited by 10
“Further evidence showed that IL-25 promotes cell proliferation, inhibits apoptosis (16), and affects the development of fibrosis and hypoxic ischemic injury (17), tumor metastasis (18) and metabolism processes (19, 20).”
BackgroundCalycosin prevents NLRP3-induced gut fibrosis by regulating IL-33/ST2 axis
Liao, X., Xie, H., & Yu, S. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30240 · Cited by 10
“Recently, it has been demonstrated that IL-33 play key roles in type 2 cytokine-driven inflammation and fibrosis [43]; moreover, promote ischemia-reperfusion induced renal or hepatic fibrosis in mice [44, 45].”
BackgroundAccurately measuring and modeling Th2 and Th17 endotypes in severe asthma
Hart, K. M., Choy, D. F., Bradding, P., Wynn, T. A., & Arron, J. R. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.02.07 · Cited by 9
Self-citationSingle-Chain Soluble Receptor Fusion Proteins as Versatile Cytokine Inhibitors
Holgado, A., Braun, H., Verstraete, K., Vanneste, D., Callewaert, N., Savvides, S. N., Afonina, I. S., & Beyaert, R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01422 · Cited by 9
“Thus, combinatorial treatment approaches simultaneously targeting several cytokines may improve clinical outcomes, which has also been documented for IL-33 and TSLP in preclinical studies (36).”
BackgroundAtopic Dermatitis and Type 2 Immune Deviation
Furue, M., Ulzii, D., Vu, Y. H., Tsuji, G., Kido‐Nakahara, M., & Nakahara, T. (2019) · Current Treatment Options in Allergy · doi:10.1007/s40521-019-00219-w · Cited by 10
Russo, B. F., Borowczyk, J., Cacialli, P., Moguelet, P., Truchetet, M., Modarressi, A., Brembilla, N. C., Bertrand, J., Boehncke, W., & Chizzolini, C. (2022) · Rheumatology · doi:10.1093/rheumatology/keac044 · Cited by 8
Ullah, R., Khan, J., Basharat, N., Huo, D., Din, A. U., & Wang, G. (2022) · Viruses · doi:10.3390/v14102149 · Cited by 11
“Further evidence showed that IL-25 promotes cell proliferation, inhibits apoptosis [73], and affects the development of fibrosis and hypoxicischemic injury [6,74], tumor metastasis [75] and metabolism processes [76,77].”
BackgroundTSLP links intestinal nutrient sensing with amplification of the ILC2–tuft cell circuit
Liao, C., Mennillo, E., Kattah, M. G., Ji, M., Wang, Z., Drucker, D. J., Liang, H.-E., & Locksley, R. M. (2025) · Nature Immunology · doi:10.1038/s41590-025-02328-y · Cited by 12
“The combinatorial role of alarmins in regulating the activation of tissue resident ILC2s and Th2 cells 10,11 prompted us to consider roles for additional alarmins in small intestinal physiology and homeostasis.”
Maggi, L., Camelo, G. M. A., Rocha, I. C., Alves, W. P., Moreira, J. M. P., Pereira, T. A., Tafuri, W. L., Rabelo, É. M. L., Corrêa, A., Ecco, R., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210237 · Cited by 7
“IL-33 is an alarmin released by resident liver cells, such as hepatocytes, endothelial cells, and HSCs, when Schistosoma eggs injure the host’s tissues [33,34].”
BackgroundResultInfluentialLiu, B., Jiang, Q., Chen, R., Zhang, H., Xia, Q., Shao, C., Liu, X., Wang, M., Shi, Y., Zhu, J., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111999 · Cited by 8
New perspectives on the initiation of allergic immune responses at barrier sites
Noti, M. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.07.001 · Cited by 8
Derecki, N. C., Alemán-Muench, G. R., Lewis, G. M., Banie, H., Eckert, W. A., He, Y., Fourgeaud, L., Rao, S., Ma, J. Y., Carreira, V., et al. (2019) · SSRN Electronic Journal · doi:10.2139/ssrn.3414004 · Cited by 7
Shi, W., Kaewsanmung, S., Kiratipaisarl, W., & Sapbamrer, R. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1721233 · Cited by 7
Knockdown of Cadherin 26 Prevents the Inflammatory Responses of Allergic Rhinitis
Liu, T., Sun, Y., Guo, Z., & Bai, W. (2022) · The Laryngoscope · doi:10.1002/lary.30380 · Cited by 6
“The pathological effects of these innate factors are directly related to the enhanced production of IL-4, IL-5, and IL-13 by downstream target cells such as CD4 Th2 cells.(22) The transcription factor GATA-3 expressed in naive T cells, is strongly upregulated during Th2 development.”
BackgroundHansakon, A., Jeerawattanawart, S., & Angkasekwinai, P. (2023) · Scientific Reports · doi:10.1038/s41598-023-37158-1 · Cited by 6
Immunological disturbance effect of exogenous histamine towards key immune cells
Liu, Y., Li, H., Wang, C., Chen, S., Lian, R., Wang, W., Fu, L., & Wang, Y. (2023) · Food Science and Human Wellness · doi:10.26599/fshw.2022.9250154 · Cited by 6
Pathological and therapeutic roles of innate lymphoid cells in diverse diseases
Kim, J., Kim, G., & Min, H. (2017) · Archives of Pharmacal Research · doi:10.1007/s12272-017-0974-2 · Cited by 7
“On the other hand, blocking of alarmins may affect multiple cell types or have no effects owing to their redundant activities toward ILC2s (Cayrol and Girard 2014; Vannella et al. 2016).”
BackgroundFerroptosis: A New Strategy for the Treatment of Fibrotic Diseases
Pei, Z., Fan, J., Tang, M., & Li, Y. (2024) · Advanced Biology · doi:10.1002/adbi.202400383 · Cited by 7
Role of alarmin cytokines and microRNAs in the host-schistosome interaction
He, X., & Pan, W. (2018) · F1000Research · doi:10.12688/f1000research.15695.1 · Cited by 5
Yang, Y., Lan, Y., Bian, L., Li, Y., Song, Q., Gao, X., Hou, Q., Bai, Y., & Chen, B. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08012-5 · Cited by 4
“In our clinical trials, we will select subjects with elevated Th2 cytokines (IL-4, IL-5, IL-13) through pharmacodynamic markers (PD markers) to ensure relevance to the targeted mechanism of action of CM512 [35–37].”
Pimpalwar, N., Celik, S., Sadegh, M. K., Czuba, T., Gidlöf, O., & Smith, J. G. (2024) · The FASEB Journal · doi:10.1096/fj.202302000rr · Cited by 6
Garrido, C. V., Nair, P. K., Davila, I. J., & de Llano, L. P. (2024) · Journal of Investigational Allergology and Clinical Immunology · doi:10.18176/jiaci.1012 · Cited by 6
“Consistent with this principle, targeting all 3 alarmins (TSLP, IL-25, and IL-33) was found to be more effective than blocking a single alarmin in chronic models of helminth infection and T2 cytokine–driven lung inflammation [86].”
BackgroundMiranda, G. S., Rodrigues, J. G. M., de Rezende, M. C., Resende, S. D., Camelo, G. M. A., Silva, J. K. A. D. O., Maggi, L., Rodrigues, V. F., de Oliveira, V. G., & Negrão‐Corrêa, D. A. (2022) · Parasitology · doi:10.1017/s0031182022000774 · Cited by 4
Targeting cytokines in asthma therapy: could IL-37 be a solution?
Wegmann, M. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1354701 · Cited by 4
“Combinatorial targeting of the three cytokines TSLP, IL-25, and IL-33 displayed synergistic anti-inflammatory effects in a mouse model of TH2-type inflammation, highlighting the potential of such combined targeting strategies [28].”
BackgroundThe Interleukin 33–T Helper 2 Cell Axis Promotes Human Liver Fibrosis
Lurje, I., & Tacke, F. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2024.01.004 · Cited by 4
Telocytes link epithelial nutrient sensing with amplification of the ILC2-tuft cell circuitPreprint
Liao, C., Ji, M., Wang, Z., Drucker, D. J., Liang, H.-E., & Locksley, R. M. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.14.618111 · Cited by 4
Cellular Cosmetics: How Innate Lymphoid Cells Can Recontour the Tumour Microenvironment
Pun, N., & Withers, D. R. (2025) · European Journal of Immunology · doi:10.1002/eji.70041 · Cited by 4
Sbierski‐Kind, J., Cautivo, K. M., Nilsson, J., Wagner, J., Dahlgren, M. W., Ewing-Crystal, N. A., Krasilnikov, M., Mroz, N. M., Ganslmeier, M., Lizama, C. O., et al. (2026) · Science Advances · doi:10.1126/sciadv.aea6805 · Cited by 3
“Excess IL-33, IL-25, and TSLP, all tissue cytokines that drive type 2 immunity, can each lead to organ fibrosis ( 24 , 29 , 69 ), with combinatorial targeting of all three signals reducing type 2–driven inflammation and fibrosis in infectious parasitic models ( 53 , 70 ).”
Cao, C.-J., Yang, M., Du, C., Fang, X., Song, H.-H., Wang, W.-J., Wang, M.-M., Zhang, W., Liu, Z.-L., Huang, C., et al. (2026) · Inflammation · doi:10.1007/s10753-026-02506-6 · Cited by 3
“Interleukins, particularly IL-25, are well-established mediators of intercellular communication and have been implicated in fibrotic progression [44–46 ].”
Novel Therapeutic Strategies Targeting Fibroblasts to Improve Heart Disease
Li, Y. (2024) · Journal of Cellular Physiology · doi:10.1002/jcp.31504 · Cited by 4
Fibrose der Haut: Neue Erkenntnisse in Pathophysiologie und Therapie
Willenborg, S., Satzinger, S., & Eming, S. A. (2024) · Die Dermatologie · doi:10.1007/s00105-024-05299-7 · Cited by 2
Immune cells in liver regeneration: Current evidence and potential clinical targets
Moore, H. F., Usmani, S., Froghi, S., Rashidi, H., Quaglia, A., Fuller, B. J., & Davidson, B. R. (2025) · International Reviews of Immunology · doi:10.1080/08830185.2025.2531820 · Cited by 4
“ILC2 effector function is dependent on exposure to IL-25, IL-33 and TSLP, indicating the role of a local tissue-derived checkpoint in the activation and differentiation of ILC2 [173].”
Malekshah, R. E., Karim, A., Guo, C., Chu, Y., Yang, F., Hsu, S., & Hsu, S. C. (2026) · ChemBioChem · doi:10.1002/cbic.202500756 · Cited by 2
Downregulation of SLC40A1 leads to iron accumulation in fibrotic lung fibroblasts
Dang, Q., Huang, C., Liang, Y., Surendran, A. M., Muthiah, D., Vaddadi, K., Hewawasam, S., Mills, T. W., & Liu, L. (2026) · Respiratory Research · doi:10.1186/s12931-025-03479-0 · Cited by 3
“Means ± SE, * p 0.05, and *** p 0.001, Two-way ANOVA, followed by uncorrected Fisher’s least significant difference (LSD) test in fibroblast activation and fibrosis development [34, 35].”
Influentialzhang, J., Liu, X., Qi, Q., Pan, Y., Zeng, R., Qiao, C., Xu, C., Wang, P., Shi, S., Wang, Y. L., et al. (2026) · Research · doi:10.34133/research.1190 · Cited by 2
“While identifying more effective potential therapeutic targets is important for improving asthma outcomes, it is equally crucial to develop a deeper understanding of the immune micro-environment in asthma and to ascertain the optimal timing for the administration of existing drugs [ 7 ].”
R, S. H., Dhanush, Y., Cuddapah, R., Kumar, S. N., & Ganesh, V. S. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12005-4 · Cited by 2
“[116] extended this observation to a model of type-2-driven fibrosis, demonstrating that combined alarmin blockade was necessary to achieve full suppression of fibrotic remodelling [116].”
Practical Review of Biologics in Chronic Rhinosinusitis With Nasal Polyps
Lee, K., Ryu, G., Yoo, S. H., Kim, Y. M., Mo, J., & Shin, S. (2021) · Journal of rhinology · doi:10.18787/jr.2021.00382 · Cited by 2
Montasser, A., Dakrory, A. I., Ibrahim, M., Zayyat, E. E., Tallima, H., & Ridi, R. E. (2024) · Infection and Immunity · doi:10.1128/iai.00362-24 · Cited by 2
“As constantly reported (19–22), SEA released from egg granulomas elicited the production of the alarmins and It is established that trapped eggs secrete SEA, which principally elicit the production of type 2 cytokines by hepatic cells (3–10).”
Maes, T., & Brusselle, G. (2019) · Respirology · doi:10.1111/resp.13748 · Cited by 2
Kiboneka, A. (2020) · World Journal of Advanced Research and Reviews · doi:10.30574/wjarr.2020.8.3.0315 · Cited by 1
“The National Asthma Education and Prevention Program and Global Initiative for Asthma guidelines divide asthma severity based on lung function (FEV1), daytime and nocturnal symptoms, and frequency of rescue bronchodilator use [4, 5].”
BackgroundResultInfluentialAdamu, R. M., Ibrahim, M. A., Uba, A. İ., Fadare, O. A., & Muthukumaran, J. (2024) · Chemical Papers · doi:10.1007/s11696-024-03471-w · Cited by 1
“The TSLP, IL-33 In the context of allergic diseases, disrupting the signaling of cytokine alarmins collectively has been shown to have a suppressive effect on chronic and progressive type-2 cytokines, which are central players in allergic responses (Vannella et al. 2016).”
Tezepelumab improved chronic eosinophilic pneumonia in severe asthma patients with liver cirrhosis
Inaba, M., Shimizu, Y., Nakamura, Y., Okutomi, H., Takemasa, A., & Niho, S. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1381261 · Cited by 1
Tu, W., Wu, M., Wan, R., Alphonse, M., Gu, W., Ghosh, B., Lin, J., Zhang, Y., Chen, J., Hu, X., et al. (2026) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2026.01.016 · Cited by 2
Biomarkers for chronic obstructive pulmonary disease (COPD) with type-2 inflammation
Pathak, C., Cox, J., Suri, R., & Akuthota, P. (2026) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2026.06.035 · Cited by 1
COPD Biologics: Right Patient, Right Pathway, Right Time
Finney, L., Conway, F. M., & Sethi, D. (2026) · Pulmonary Therapy · doi:10.1007/s41030-026-00370-1 · Cited by 2
“However, TSLP also acts directly on ILC2s and mast cells driving T2 inflammation as well as contributing to tissue fibrosis [82–84].”
Collaborative functionality between three types of inflammation in idiopathic pulmonary fibrosis
Fabre, T., Wynn, T. A., & Hart, K. M. (2026) · Nature Immunology · doi:10.1038/s41590-026-02616-1 · Cited by 2
“https://doi.org/10.1038/s41590-026-02616-1 stromal lymphopoietin (TSLP), all of which are significantly enriched in IPF lungs 34,90–94 .”
InfluentialSelf-citationLiao, Z., Tu, B., Sun, L., Dong, C., Jiang, H., & Hu, G. (2022) · European Journal of Inflammation · doi:10.1177/1721727x221094158 · Cited by 2
Association between IL-25, IL-33 and atopic dermatitis: A systematic review and meta-analysis
Zhou, B., Yue, X., Liang, S., Shang, S., Xiang, L., Zhou, K., & Li, L. (2023) · European Journal of Inflammation · doi:10.1177/1721727x231183670 · Cited by 1
Labuda, J. C., Olsen, T. M., Verma, S., Kimmel, S., Edwards, T. H., Dufort, M. J., & Harrison, O. J. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkaf138 · Cited by 1
Souza, C. O. S. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2021.tde-05112021-095928
El-Naccache, D. W., Chen, F., Palma, M., Lemenze, A. D., Wu, W., Mishra, P. K., Eltzschig, H. K., Robson, S. C., Virgilio, F. D., Edelblum, K. L., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3927432
Severe polypous rhinosinusitis associated with non-allergic bronchial asthma
Shilovskiy, I. P., Kurbacheva, O. M., Dyneva, M. E., Timoshenko, D. O., Savushkina, E. Y., Савлевич, Е. Л., Егоров, В. И., Rusak, T. E., Kovchina, V. I., Аркадьевич, Н. А., et al. (2023) · Immunologiya · doi:10.33029/1816-2134-2023-44-6-731-753 · Cited by 1
Schulze, T. T., Neville, A. J., Ehrhorn, E. G., Alsuleiman, S. A., Vennerstrom, J. L., & Davis, P. H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1527129
Yang, Y. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s588680
Necroptosis in asthma: a critical driver of immune dysregulation and airway remodeling
Ni, F.-X., Ren, S.-C., Hu, J., Chen, P.-S., Chen, H.-H., Huang, D., & Jiang, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1783960
“These are not merely released; they are released in their fully active or rapidly activatable forms (144).”
The IL-33-ILC2 axis: a key regulator of type 2 immunity in respiratory disease
Zhu, Y., Zhang, Y., & Cheng, R. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1891857 · Cited by 1
Interleukin 4-receptor-α blockade in localised scleroderma: a phase 2 proof-of-concept study
Eming, S. A., Kreuter, A., Hahn, M., Ghoreschi, K., Moinzadeh, P., Hunzelmann, N., Becker, K., Reiche, N., Adams, A., Shah‐Hosseini, K., et al. (2026) · Annals of the Rheumatic Diseases · doi:10.1016/j.ard.2026.09.022
Metadata
- Authors
- Vannella, K. M., Ramalingam, T. R., Borthwick, L. A., Barron, L., Hart, K. M., Thompson, R. W., Kindrachuk, K. N., Cheever, A. W., White, S., Budelsky, A. L., Comeau, M. R., Smith, D. E., & Wynn, T. A.
- Affiliations
- National Institutes of Health (US)
- Amgen (United States) (US)
- Corresponding author
- Wynn, Thomas A.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2016-05-04
- Volume
- 8
- Issue
- 337
- Pages
- 337ra65-337ra65
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2345448809
- Cited by
- 188
- References
- 64
- Citations by year
- 2026: 15 · 2025: 10 · 2024: 19 · 2023: 13 · 2022: 21 · 2021: 18 · 2020: 19 · 2019: 24 · 2018: 20 · 2017: 25 · 2016: 4
- FWCI
- 14.73
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Intramural Research Program of NIH
- National Institute of Allergy and Infectious Diseases
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › IL-33, ST2, and ILC Pathways
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Life Sciences › Immunology and Microbiology › Parasitology › Parasites and Host Interactions
- Keywords
- thymic stromal lymphopoietin, IL-25, IL-33, ST2, type 2 inflammation, fibrosis, helminthiasis, Schistosoma mansoni, lung granulomas, eosinophils, ILC2, IL-13, IL-4, allergic lung inflammation, house dust mites, mucus production, lung remodeling, monoclonal antibodies
- MeSH terms
- Interleukin-33, Thymic Stromal Lymphopoietin, Animals, Antibodies, Monoclonal, Female, Fibrosis, Granuloma, Inflammation, Lung Neoplasms, Male, Mice, Inbred BALB C, Mice, Inbred C57BL, Schistosoma mansoni, Interleukin-4, Cytokines, Mice, Knockout, Interleukin-13, Interleukin-17, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.